FDA warns consumers about homeopathic teething products

The FDA is warning consumers that homeopathic teething tablets containing belladonna pose an unnecessary risk to infants and children and urges consumers not to use these products and dispose of any in their possession.

FDA has completed testing of homeopathic teething tablets labeled as containing belladonna and other ingredients and marketed by CVS and Hyland’s Inc. Our testing found that the belladonna alkaloids (atropine and scopolamine) content and coffea cruda (caffeine) content is not uniform among the manufactured tablets. FDA analysis found the levels of atropine and scopolamine in some of the CVS tablets and the levels of scopolamine in some of the Hyland’s tablets far exceeded the amount stated on the products’ labels. See Laboratory Analysis of Homeopathic Teething Tablets for more information.

Additional Information

• FDA announces Standard Homeopathic Company's nationwide voluntary recall of Hyland's teething tablets (4/30/2017)
• FDA confirms elevated levels of belladonna in certain homeopathic teething products (1/27/2017)
• FDA warns against the use of homeopathic teething tablets and gels (9/30/2016)
• FDA issues warning letter to Raritan Pharmaceuticals (6/20/2017)
• FDA issues warning letter to Homeolab USA Inc. (8/2/2017)
  FDA issues warning letter to Nova Homeopathic Therapeutics Inc. (9/1/2017)
• Teething Tablets: Questions and Answers
• Medication Disposal: Questions and Answers
• Do Teething Babies Need Medicine on Their Gums? No
• FDA Adverse Event Reporting Systems (FAERS) - Teething tablet AERS Part 1 of 3
• FDA Adverse Event Reporting Systems (FAERS) - Teething tablet Part 2 of 3
• FDA Adverse Event Reporting Systems (FAERS) - Teething tablet Part 3 of 3

Back to Top